Combining cancer immunotherapy with the IAP‐antagonizing activity of SM to enhance TNF‐ and TRAIL‐mediated cancer cell killing via cytotoxic lymphocytes is therefore a reasonable therapeutic approach. This evidence concerns the gene TNF and cancer.